See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eurovision
Manchester City
Social Media
Baseball
MLB
South America
Artificial Intelligence
NBA
Formula 1
Donald Trump
Soccer
Natural Disasters
Published • loading... • Updated

Nicox releases results from Whistler phase 3b trial in IOP lowering eye drops

Summary by ophthalmologytimes.com
NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analog).
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All
Left
Center
Right
ophthalmologytimes.comophthalmologytimes.com
Reposted by
optometrytimes.comoptometrytimes.com

Nicox releases results from Whistler phase 3b trial in IOP lowering eye drops

NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop with a dual mechanism of action (nitric oxide and prostaglandin analog).

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

ophthalmologytimes.com broke the news in on Thursday, May 15, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Whistler

Whistler

News
For You
SearchBlindspotLocal